Sernova Update on Strategic Initiatives
Sernova Corp (TSX: SVA, OTCQB: SEOVF) announced key strategic initiatives, including a non-binding letter of intent with HealthGena and GOLDTRACK Ventures for 'Project REEM Ventures' to explore product development and commercialization opportunities in Saudi Arabia for type 1 diabetes treatment. The company also welcomed Dr. Robert Gabbay, former Chief Scientific and Medical Officer at the American Diabetes Association, as a clinical advisor. Sernova will host a virtual Town Hall on December 13 and hold its Annual General Meeting on January 7, 2025. The company is developing a Cell Pouch bio-hybrid organ as a potential functional cure for type 1 diabetes and thyroid disorders.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) ha annunciato iniziative strategiche chiave, tra cui una lettera di intenti non vincolante con HealthGena e GOLDTRACK Ventures per il 'Progetto REEM Ventures' per esplorare opportunità di sviluppo e commercializzazione di prodotti in Arabia Saudita per il trattamento del diabete di tipo 1. L'azienda ha anche accolto il Dott. Robert Gabbay, ex Chief Scientific and Medical Officer dell'American Diabetes Association, come consulente clinico. Sernova ospiterà un Town Hall virtuale il 13 dicembre e terrà la sua Assemblea Generale Annuale il 7 gennaio 2025. L'azienda sta sviluppando un organo ibrido bio-cellulare Cell Pouch come una potenziale cura funzionale per il diabete di tipo 1 e disturbi della tiroide.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) anunció iniciativas estratégicas clave, incluyendo una carta de intención no vinculante con HealthGena y GOLDTRACK Ventures para 'Proyecto REEM Ventures' para explorar oportunidades de desarrollo y comercialización de productos en Arabia Saudita para el tratamiento de la diabetes tipo 1. La compañía también dio la bienvenida al Dr. Robert Gabbay, ex Chief Scientific and Medical Officer de la American Diabetes Association, como asesor clínico. Sernova organizará un Town Hall virtual el 13 de diciembre y llevará a cabo su Asamblea General Anual el 7 de enero de 2025. La compañía está desarrollando un órgano bio-híbrido Cell Pouch como una posible cura funcional para la diabetes tipo 1 y trastornos tiroideos.
서노바 코프 (TSX: SVA, OTCQB: SEOVF)는 1형 당뇨병 치료를 위한 제품 개발 및 상업화 기회를 탐색하기 위해 Saudi Arabia의 HealthGena 및 GOLDTRACK Ventures와 '프로젝트 REEM Ventures'에 대한 비구속적 양해각서를 포함한 주요 전략 이니셔티브를 발표했습니다. 이 회사는 또한 로버트 가베이 박사(전 미국당뇨병협회 수석 과학 및 의료 책임자)를 임상 고문으로 맞이했습니다. 서노바는 12월 13일 가상 타운홀을 개최하고, 2025년 1월 7일 연례 총회를 개최할 예정입니다. 이 회사는 1형 당뇨병 및 갑상선 장애를 위한 잠재적 기능적 치료제로 Cell Pouch 생체 하이브리드 장기를 개발하고 있습니다.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) a annoncé des initiatives stratégiques clés, y compris une lettre d'intention non contraignante avec HealthGena et GOLDTRACK Ventures pour le 'Projet REEM Ventures' afin d'explorer les opportunités de développement et de commercialisation de produits en Arabie Saoudite pour le traitement du diabète de type 1. La société a également accueilli Dr Robert Gabbay, ancien Chief Scientific and Medical Officer de l'American Diabetes Association, en tant que conseiller clinique. Sernova organisera une assemblée virtuelle le 13 décembre et tiendra son Assemblée Générale Ordinaire le 7 janvier 2025. L'entreprise développe un organe bio-hybride Cell Pouch comme une potentielle guérison fonctionnelle pour le diabète de type 1 et les troubles thyroïdiens.
Sernova Corp (TSX: SVA, OTCQB: SEOVF) hat wichtige strategische Initiativen angekündigt, darunter ein nicht verbindliches Absichtsschreiben mit HealthGena und GOLDTRACK Ventures für 'Projekt REEM Ventures', um Produktentwicklungs- und Kommerzialisierungsmöglichkeiten in Saudi-Arabien zur Behandlung von Typ-1-Diabetes zu erkunden. Das Unternehmen begrüßte auch Dr. Robert Gabbay, ehemaliger Chief Scientific and Medical Officer der American Diabetes Association, als klinischen Berater. Sernova wird am 13. Dezember eine virtuelle Bürgerversammlung ausrichten und am 7. Januar 2025 seine Hauptversammlung abhalten. Das Unternehmen entwickelt ein bio-hybrides Organ, den Cell Pouch, als potenzielle funktionelle Heilung für Typ-1-Diabetes und Schilddrüsenerkrankungen.
- Strategic expansion into Saudi Arabian market through Project REEM Ventures
- Addition of high-profile diabetes expert Dr. Robert Gabbay as clinical advisor
- None.
Signed Letter of Intent with ‘Project REEM Ventures’ for Product Development and Commercialization in the Kingdom of Saudi Arabia
Renowned Diabetes Expert Dr. Robert Gabbay to Serve as Clinical Advisor
Town Hall Call to be Held on December 13; AGM Circular Available on December 6
LONDON, Ontario and BOSTON, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Sernova Corp. (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its Cell Pouch bio-hybrid organ as a functional cure for type 1 diabetes, today announced key initiatives that underscore the company’s strategic progress.
On November 12, at the Riyadh Global Medical Biotechnology Summit, Sernova entered into a non-binding letter of intent with HealthGena and GOLDTRACK Ventures regarding ‘Project REEM Ventures’ to explore opportunities for product development and commercialization initiatives in the Kingdom of Saudi Arabia to address the growing incidence of type 1 diabetes. ‘Project REEM Ventures’ is a collaboration initiative between Sernova, HealthGena and GOLDTRACK Ventures. HealthGena is a Riyadh-based business accelerator with a focus on biotechnology innovation. GOLDTRACK Ventures is a German-regulated venture capital manager based in Leipzig, Germany, specializing in Life Science investments. A definitive agreement has not been entered into.
Additionally, Sernova is honored to welcome Dr. Robert Gabbay who will serve in a clinical advisory role. Dr. Gabbay brings a significant wealth of expertise in diabetes care and research, having most recently served as Chief Scientific and Medical Officer at the American Diabetes Association, and previously as Chief Medical Officer at the Joslin Diabetes Center, one of the world’s leading diabetes research organizations. His expertise will be instrumental as Sernova advances in clinical trial development and product innovation.
“With our Cell Pouch bio-hybrid organ, Sernova is at the cutting edge of developing a potentially transformative functional cure for type 1 diabetes,” stated Jonathan Rigby, CEO of Sernova. “Our ongoing discussions with our visionary partners at GOLDTRACK Ventures and HealthGena, plus the addition of Dr. Gabbay as an advisor signify positive progress towards achievement of our strategic goals.”
Under new leadership, Sernova is committed to transparency and fostering engagement with its shareholders and will host a virtual Town Hall for investors on Friday, December 13, at 10:00am ET. The event will feature the company’s recently appointed CEO, Jonathan Rigby, who will discuss recent developments and Sernova’s strategic plans to create long-term value for shareholders. This will be followed by an open forum for questions and answers. The webcast registration link will soon be available in the Investor section of the company’s website at https://sernova.com/.
In addition, the Company is holding an Annual General and Special Meeting of Shareholders on January 7, 2025. The Management Information Circular for the meeting will be available on the Company’s website on December 6, 2024.
ABOUT SERNOVA CORP
Sernova Corp. is a clinical-stage company developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cells to create a bio-hybrid organ. A bio-hybrid organ refers to a medical device designed to be implanted into the human body, where it integrates with existing living tissue to replicate or enhance the function of a natural organ, essentially aiming to restore normal organ function by combining living cells with non-living materials to mimic the properties of the original organ and seamlessly interact with surrounding tissues. This innovative approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes and thyroid disorders.
FOR FURTHER INFORMATION, PLEASE CONTACT:
David Burke VP, Investor Relations (917) 751-5713 Email: David.Burke@sernova.com Website: https://sernova.com/
The TSX has not reviewed this news release and does not accept responsibility for the accuracy or adequacy of this news release. FORWARD-LOOKING INFORMATION This press release contains forward-looking statements within the meaning of applicable Canadian securities laws. Forward-looking statements in this press release include our belief of potential opportunities for product development and commercialisation initiatives in the Kingdom of Saudi Arabia and our progress towards achieving our strategy goals. With respect to the forward-looking statements contained in this press release, Sernova has made numerous assumptions regarding, among other things: the company’s ability to secure additional financing on reasonable terms, or at all; and the ability to conduct all required preclinical and clinical studies for the company’s Cell Pouch, including the timing and results of those trials. A more complete discussion of the risks and uncertainties facing Sernova appears in Sernova’s Annual Information Form for the year ended October 31, 2023 filed with Canadian securities authorities and available at www.sedarplus.ca, as updated by Sernova’s continuous disclosure filings, which are available at www.sedarplus.ca. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Sernova disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.
FAQ
What is Project REEM Ventures and how does it affect Sernova (SEOVF)?
When is Sernova's (SEOVF) upcoming Town Hall meeting in December 2024?
Who is the new clinical advisor for Sernova (SEOVF) announced in December 2024?
